REFERENCES
1. Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome? Metab Target Organ Damage 2024;4:10.
2. Younossi ZM. Non-alcoholic fatty liver disease-a global public health perspective. J Hepatol 2019;70:531-44.
3. Wang S, Friedman SL. Found in translation-fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Transl Med 2023;15:eadi0759.
4. Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology 2020;158:1967-83.e1.
5. Díaz LA, Villota-Rivas M, Barrera F, Lazarus JV, Arrese M. The burden of liver disease in Latin America. Ann Hepatol 2024;29:101175.
6. Shaheen M, Pan D, Schrode KM, et al. Reassessment of the hispanic disparity: hepatic steatosis is more prevalent in mexican americans than other hispanics. Hepatol Commun 2021;5:2068-79.
7. Shaheen M, Schrode KM, Pan D, et al. Sex-specific differences in the association between race/ethnicity and NAFLD among US population. Front Med (Lausanne) 2021;8:795421.
8. Driessen S, Francque SM, Anker SD, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology 2023;Online ahead of print.
9. Yan L, Hu X, Wu S, Cui C, Zhao S. Association between the cardiometabolic index and NAFLD and fibrosis. Sci Rep 2024;14:13194.
10. Hirata A, Harada S, Iida M, et al. Association of nonalcoholic fatty liver disease with arterial stiffness and its metabolomic profiling in japanese community-dwellers. J Atheroscler Thromb 2024;31:1031-47.
11. Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005;54:142-51.
12. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024;390:497-509.
13. Sevastianova K, Kotronen A, Gastaldelli A, et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011;94:104-11.
14. Wang CW, Lin HY, Shin SJ, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int 2011;31:1326-31.
15. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts 2024;17:374-444.
16. Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol 2023;79:1557-65.
17. Puengel T, Tacke F. Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today? Expert Opin Pharmacother 2024;25:1249-63.
18. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-90.
19. Loomba R, Abdelmalek MF, Armstrong MJ, et al; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:511-22.
20. Speliotes EK, Butler JL, Palmer CD, Voight BF, et al; Hirschhorn JN; GIANT Consortium; MIGen Consortium; NASH CRN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904-12.
21. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
22. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009;58:2616-23.
23. Petit JM, Guiu B, Masson D, et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010;95:E430-6.
24. Chen LZ, Xin YN, Geng N, Jiang M, Zhang DD, Xuan SY. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol 2015;21:794-802.
25. Lee CC, Haffner SM, Wagenknecht LE, et al. Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS family study. Diabetes Care 2013;36:901-7.
26. Shah MH, Piaggi P, Looker HC, Paddock E, Krakoff J, Chang DC. Lower insulin clearance is associated with increased risk of type 2 diabetes in native Americans. Diabetologia 2021;64:914-22.
27. Matveyenko AV, Liuwantara D, Gurlo T, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes 2012;61:2269-79.
28. Lee WH, Najjar SM, Kahn CR, Hinds TD Jr. Hepatic insulin receptor: new views on the mechanisms of liver disease. Metabolism 2023;145:155607.
29. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 2018;19:31-44.
31. Najjar SM, Caprio S, Gastaldelli A. Insulin clearance in health and disease. Annu Rev Physiol 2023;85:363-81.
32. Meijer RI, Barrett EJ. The insulin receptor mediates insulin’s early plasma clearance by liver, muscle, and kidney. Biomedicines 2021;9:37.
33. Najjar SM, Perdomo G. Hepatic insulin clearance: mechanism and physiology. Physiology (Bethesda) 2019;34:198-215.
35. Bergman RN, Piccinini F, Kabir M, Kolka CM, Ader M. Hypothesis: role of reduced hepatic insulin clearance in the pathogenesis of type 2 diabetes. Diabetes 2019;68:1709-16.
36. Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol 2018;217:2273-89.
37. Kolka CM, Bergman RN. The barrier within: endothelial transport of hormones. Physiology (Bethesda) 2012;27:237-47.
38. Najjar SM, Philippe N, Suzuki Y, et al. Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 1995;34:9341-9.
39. Najjar SM, Accili D, Philippe N, Jernberg J, Margolis R, Taylor SI. pp120/ecto-ATPase, an endogenous substrate of the insulin receptor tyrosine kinase, is expressed as two variably spliced isoforms. J Biol Chem 1993;268:1201-6.
40. Sundberg U, Beauchemin N, Obrink B. The cytoplasmic domain of CEACAM1-L controls its lateral localization and the organization of desmosomes in polarized epithelial cells. J Cell Sci 2004;117:1091-104.
41. Formisano P, Najjar SM, Gross CN, et al. Receptor-mediated internalization of insulin. Potential role of pp120/HA4, a substrate of the insulin receptor kinase. J Biol Chem 1995;270:24073-7.
42. Najjar SM, Yang Y, Fernström MA, et al. Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2005;2:43-53.
43. Najjar SM, Abdolahipour R, Ghadieh HE, et al. Regulation of insulin clearance by non-esterified fatty acids. Biomedicines 2022;10:1899.
44. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 2000;275:32379-82.
45. Ter Horst KW, Vatner DF, Zhang D, et al. Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease. Diabetes Care 2021;44:489-98.
46. Zaharia OP, Antoniou S, Bobrov P, et al; GDS Group. Reduced insulin clearance differently relates to increased liver lipid content and worse glycemic control in recent-onset type 2 and type 1 diabetes. Diabetes Care 2023;46:2232-9.
48. Bojsen-Møller KN, Lundsgaard AM, Madsbad S, Kiens B, Holst JJ. Hepatic insulin clearance in regulation of systemic insulin concentrations-role of carbohydrate and energy availability. Diabetes 2018;67:2129-36.
51. Tricò D, Galderisi A, Mari A, et al. Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: a cross-sectional and longitudinal study from the Yale Pediatric NAFLD cohort. Diabetes Obes Metab 2020;22:1628-38.
52. Pivovarova O, Bernigau W, Bobbert T, et al. Hepatic insulin clearance is closely related to metabolic syndrome components. Diabetes Care 2013;36:3779-85.
53. Smith K, Taylor GS, Peeters W, et al. Elevations in plasma glucagon are associated with reduced insulin clearance after ingestion of a mixed-macronutrient meal in people with and without type 2 diabetes. Diabetologia 2024;Online ahead of print.
54. Ghadieh HE, Russo L, Muturi HT, et al. Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis. Metabolism 2019;93:33-43.
55. Poy MN, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver. Nat Genet 2002;30:270-6.
56. Russo L, Muturi HT, Ghadieh HE, et al. Liver-specific reconstitution of CEACAM1 reverses the metabolic abnormalities caused by its global deletion in male mice. Diabetologia 2017;60:2463-74.
57. Watada H, Tamura Y. Impaired insulin clearance as a cause rather than a consequence of insulin resistance. J Diabetes Investig 2017;8:723-5.
58. Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014;59:2178-87.
59. Ramakrishnan SK, Khuder SS, Al-Share QY, et al. PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition. J Biol Chem 2016;291:8121-9.
60. Al-Share QY, DeAngelis AM, Lester SG, et al. Forced hepatic overexpression of CEACAM1 curtails diet-induced insulin resistance. Diabetes 2015;64:2780-90.
61. Russo L, Ghadieh HE, Ghanem SS, et al. Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. J Lipid Res 2016;57:2163-75.
62. Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. Diagn Pathol 2011;6:40.
63. Zaidi S, Asalla S, Muturi HT, et al. Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. Eur J Clin Invest 2024;54:e14177.
64. DeAngelis AM, Heinrich G, Dai T, et al. Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes 2008;57:2296-303.
65. Ghosh S, Kaw M, Patel PR, et al. Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med 2010;2010:69-78.
66. Helal RA, Russo L, Ghadieh HE, et al. Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. Metabolism 2021;121:154801.
67. Xu E, Dubois MJ, Leung N, et al. Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. Endocrinology 2009;150:3503-12.
68. Brunt EM, Kleiner DE, Carpenter DH, et al; American Association for the Study of Liver Diseases NASH TASK FORce. NAFLD: reporting histologic findings in clinical practice. Hepatology 2021;73:2028-38.
70. Jophlin LL, Koutalos Y, Chen C, Shah V, Rockey DC. Hepatic stellate cells retain retinoid-laden lipid droplets after cellular transdifferentiation into activated myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2018;315:G713-21.
71. Hellemans K, Michalik L, Dittie A, et al. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003;124:184-201.
72. Kostadinova R, Montagner A, Gouranton E, et al. GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci 2012;2:34.
73. Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Mol Cell Biol 2009;29:3286-96.
74. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997;94:4312-7.
75. Muturi HT, Ghadieh HE, Asalla S, et al. Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. Mol Metab 2024;88:102010.
76. Muturi HT, Ghadieh HE, Abdolahipour R, et al. Loss of CEACAM1 in endothelial cells causes hepatic fibrosis. Metabolism 2023;144:155562.
77. Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci U S A 2013;110:16975-80.
78. Najjar SM, Russo L. CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol 2014;36:55-71.
79. Abou-Rjaily GA, Lee SJ, May D, et al. CEACAM1 modulates epidermal growth factor receptor-mediated cell proliferation. J Clin Invest 2004;114:944-52.
80. Lee SJ, Heinrich G, Fedorova L, et al. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 2008;135:2084-95.
81. Lester SG, Russo L, Ghanem SS, et al. Hepatic CEACAM1 over-expression protects against diet-induced fibrosis and inflammation in white adipose tissue. Front Endocrinol (Lausanne) 2015;6:116.
82. Muturi HT, Khuder SS, Ghadieh HE, et al. Insulin sensitivity is retained in mice with endothelial loss of carcinoembryonic antigen cell adhesion molecule 1. Cells 2021;10:2093.
83. Ghadieh HE, Muturi HT, Russo L, et al. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatol Commun 2018;2:35-47.
84. Horst AK, Najjar SM, Wagener C, Tiegs G. CEACAM1 in liver injury, metabolic and immune regulation. Int J Mol Sci 2018;19:3110.
85. Nakamura K, Kageyama S, Kaldas FM, et al. Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. J Clin Invest 2020;130:2689-704.
